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Summary The Aurora kinases (serine/threonine kinases)
were discovered in 1995 during studies of mutant alleles
associatedwith abnormal spindle pole formation inDrosophila
melanogaster. They soon became the focus of much attention
because of their importance in human biology and association
with cancer. Aurora kinases are essential for cell division and
are primarily active during mitosis. Following their identifica-
tion as potential targets for cancer chemotherapy, many Aurora
kinase inhibitors have been discovered, and are currently under
development. The binding modes of Aurora kinase inhibitors
to Aurora kinases share specific hydrogen bonds between the
inhibitor core and the back bone of the kinase hinge region,
while others parts of the molecules may point to different parts
of the active site via noncovalent interactions. Currently there
are about 30 Aurora kinase inhibitors in different stages of pre-
clinical and clinical development. This review summarizes the
characteristics and status of Aurora kinase inhibitors in pre-
clinical, Phase I, and Phase II clinical studies, with particular
emphasis on the mechanisms of action and resistance to these
promising anticancer agents. We also discuss the validity of
Aurora kinases as oncology targets, on/off-target toxicities, and
other important aspects of overall clinical performance and
future of Aurora kinase inhibitors.
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Introduction
In 1995, David Glover discovered a new family of mitotic
kinases while studying mutant alleles associated with defec-
tive spindle pole organization in Drosophila melanogaster.
This family of kinases, which has been highly conserved
during evolution, became known as the Aurora kinases
(AKs) [1]. Humans have three homologous AKs, designated
A, B and C. AKs are nuclear proteins, but they each have
different sub-cellular locations. Aurora A is localized at the
centrosome from the time of centrosome duplication
through to mitotic exit [2, 3]. Aurora B, which is also known
as the chromosomal passenger protein, is localized to the
centromeres from the prophase to the metaphase-anaphase
transition. Thereafter, it is localized to midzone spindle
microtubules during telophase and subsequently to midbody
during cytokinesis [2, 3]. Aurora C is also a chromosomal
passenger protein considered to have a similar sub-cellular
location to Aurora B. Aurora C is localized to centromeres
during the prophase to metaphase and is redistributed to
midzone microtubules during anaphase [4].
AKs are known to play multiple roles in mitosis, and their
distribution correlates strongly with their functions. Aurora A
is involved in mitotic entry, separation of centriole pairs,
accurate bipolar spindle assembly, alignment of metaphase
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chromosomes, and completion of cytokinesis [5]. Re-
cently, the role of Aurora A in the promotion of nuclear
envelope breakdown has been described [6]. Aurora B
is involved in chromosomal bi-orientation, regulating
the association between kinetochores and microtubules,
and cytokinesis [7]. Aurora B is also involved in the
release of abnormal kinetochore microtubule attachments
during chromosomal bi-orientation [8]. Aurora B is
known to phosphorylate Histone H3 (Ser10), which then
aids in chromatin condensation and separation [9]. It
has been shown that Aurora C exhibits similar functions
to those assigned to Aurora B and share the same
substrates [10, 11].
Direct association with inner centromere protein
(INCENP) activates Aurora C in vivo, which results in
further complexation with Aurora B, suggesting the coop-
eration of Aurora B and C in the regulation of mitosis [10].
Like Aurora B, Aurora C associates with survivin and may
be essential for cytokinesis. Wild-type Aurora C has also
been reported to rescue multinucleation induced by enzy-
matically inactive Aurora B, indicating that Aurora C may
complement the functions of Aurora B [11]. In summary,
AKs play prominent roles in maintaining the genetic stabil-
ity of cells. Aberrant expression of AKs leads to genomic
instability or aneuploidy, hallmark of cancer cells [12].
Aurora kinases as targets for cancer therapy
The Aurora A gene was originally named BTAK (breast tumor
activated kinase) because its mRNA is overexpressed in breast
tumors and it plays a critical role in the transformation of breast
tumor cells [13]. Similarly, the Aurora A gene has been found
to be amplified in human gliomas [14]. Using Northern and
Southern blotting, Zhou et al. observed 2.5 to 8-fold amplifi-
cation of Aurora A in many tumor cell lines [15]. Furthermore,
Aurora A has been characterized as a potential low-penetrance
tumor susceptibility gene, since the Phe31Ile functional poly-
morphism is strongly associated with familial breast cancer
[16]. Similarly, Katayama et al. reported a correlation between
overexpression of Aurora B and tumor progression in surgi-
cally resected colon tumor specimens [17]. The malignant
progression of thyroid anaplastic carcinoma has also been
shown to correlate with the overexpression of Aurora B [18].
The silent functional polymorphism, Ser295Ser (885A >G) in
the C-terminal end of Aurora B has been associated with an
elevated risk of familial breast cancer [16], and overexpression
of Aurora B has been correlated with decreased survival in
glioblastoma patients [19].
In addition, aberrant expression of AKs has been shown
to impair the functions of tumor suppressor genes, thereby
generating aggressive tumors. Liu et al. reported that when
overexpressed, Aurora A specifically phosphorylates p53 at
Ser215 and inhibits its DNA binding and transcriptional
activities [20]. Thus, inhibition of Aurora A may rescue
the function of tumor suppressor genes.
Since AKs are aberrantly expressed in many cancer tissue
types, and thereby generate aggressive tumors, they are
regarded as important new-generation targets for cancer
therapy.
Small molecule Aurora kinase inhibitors (AKIs)
The discoveries of small molecule AKIs have been fuelled
by the use of a variety of experimental and theoretical
approaches. Examples include also structure-based drug
design, especially in a fragment-based setup [21–24],
structure-based virtual screening [25], FRET-based bio-
chemical cell proliferation assay [26], and rational design
followed by combinatorial expansion [27, 28].
Currently, more than 30 AKIs are in various stages of
preclinical and clinical studies. Their core binds via specific
hydrogen bonds to the hinge region of Aurora A [21, 29,
30]. The other parts of AKIs may span different regions of
the active site and interact via various types of noncovalent
interactions or stick to the solvent (Fig. 1). The interaction
modes of two clinical compounds (AT-9283 and VX-680)
and one bisanilinopyrimidine based preclinical AKI
(Genentech, Aurora A: 3 nM IC50) have determined
using PyMol, ver. 0.99 (Fig. 1).
In the following sections we discuss pan-Aurora kinase
inhibitors (Table 1), the characteristics of specific inhibitors
of Aurora A and Aurora B which are in clinical studies
(Table 2), AKIs in advanced preclinical studies (Table 3),
and finally AKIs in early preclinical studies and first gener-
ation AKIs (Table 4).
Fig. 1 The crystallographic binding modes of three AKIs (in sticks,
cyan—AT-9283, PDB (protein data bank) code 2W1E; yellow—bisa-
nilinopyrimidine-based AKI, PDB code 3H0Y, violet—VX-680, PDB
code 3E5A in the Aurora kinase A binding cleft (shown as surface).
Specific hydrogen bonds to the backbone of residues Glu-211 and Ala-
213 in the hinge region are shown by dotted lines. Color coding:
oxygen—red, nitrogen—blue, chlorine—green, carbon—different col-
ors. The figure was prepared using PyMol, ver. 0.99 [31]
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Table 1 Pan-Aurora kinase inhibitors in clinical trials
Compound, company, & code In vitro potency In vitro cellular Preclinical activity
potency (IC50)
Clinical development
PHA-739358, Nerviano [33, 34] Aurora A(IC50) - 13 nM 
Aurora B(IC50) - 79 nM 
Aurora C(IC50) - 61 nM 
28 - 300 nM Solid tumors & CML Phase II 
Advanced solid and blood 
cancers. Partial response in 
one patient. 28 patients 
displayed stable disease. 
One CML patient showed 
complete hematological 
response  
CYC116, Cyclacel [36] Aurora A(IC50) - 44 nM 
Aurora B(IC50) - 19 nM 
Aurora C(IC50) - 65 nM 
 34 - 1370 nM Solid tumors. 
Reduced tumor 
weights in various 
solid tumors & 
leukemia xenografts  
Phase I 
Advanced solid tumors 
SNS-314, Sunesis [40] Aurora A(IC50) -   9 nM 
Aurora B(IC50) - 31 nM 
Aurora C(IC50) -   3 nM 
  1.8 - 24.4 nM Solid tumors  
& leukemias 
Phase I 
Advanced solid tumors. 































Compound, Company, & Code In vitro potency In vitro cellular 
potency (IC50)    
Preclinical activity Clinical Development
VX-680, Vertex [42]
Aurora A(Ki) - 0.7 nM 
Aurora B(Ki) - 18  nM 
Aurora C(Ki) - 4.6 nM    
15 - 113 nM Solid tumors Terminated due to severe 
toxicities 
AT9283, Astex [47] Aurora     Aurora A & B(IC50) - 3 nM - Solid tumors, CML 
& AML (acute 
myeloid leukemia) 
Phase II
Refractory solid and blood 
cancers. 4 patients with 
NSCLC and colorectal 
carcinoma showed stable 
disease  
R763, Rigel [49, 50]
Aurora A(IC50) - 4.0 nM 
Aurora B(IC50) - 4.8 nM 
Aurora C(IC50) - 6.8 nM 
   2-19 nM Solid tumors Phase I 
Advanced solid tumors. 
Good tolerability and efficacy 
reported in patients. 
Hematological malignancies-





























Compound, company, & code In vitro potency In vitro cellular 
potency (IC50)    
Preclinical activity Clinical development
PF-03814375, Pfizer [53] Aurora A(IC50)  - 5.0 nMAurora B(IC50)  - 0.8 nM
   42-150 nM Solid tumors Phase I 
Advanced solid tumors.  
19 patients achieved stable 
disease 
GSK1070916, GlaxoSmithKline [56] Aurora B(IC50) - 3.5 nM
Aurora C(IC50) - 6.5 nM
  Median IC50 is  
  8 nM
Solid tumors and 
blood cancer 
xenografts. Stable 
disease in several 
solid cancer 
xenograft models  
Phase I 
Advanced solid tumors & 
leukemias
AMG-900, Amgen [57] Aurora A(IC50) - 5 nM
Aurora B(IC50) - 4 nM
Aurora C(IC50) - 1 nM
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Pan-Aurora kinase inhibitors in clinical trials
PHA-739358
PHA-739358 (Danusertib), which was discovered and devel-
oped by Nerviano Medical Sciences, is currently in Phase II
clinical studies. This inhibitor features a pyrrolopyrazole scaf-
fold which had previously been identified as an ATP-mimetic
pharmacophore suited for kinase binding [27]. The SAR
(structure activity relationship) analysis of several pyrrolopyr-
azole subclasses resulted in the synthesis of PHA-680632
which showed high anti-cancer activity in vitro and in vivo
and have thus become a preclinical candidate [27]. The X-ray
crystallographic structure of PHA-680632 in complex with
Aurora A guided further design. Through combinatorial ex-
pansion of a related 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole
core and SAR refinements of the 5-amido-pyrrolopyrazole
series a potent Aurora kinase inhibitor PHA-739358 was
identified [28]. It has been shown to inhibit Aurora A, B,
and C in biochemical competitive assays with IC50 values
of 13, 79, and 61 nM, respectively [28]. However, this study
also demonstrated that PHA-739358 predominantly has an
Aurora B inhibition phenotype in cell cultures. At high con-
centrations, it has been reported to cross-react with Abl
(Abelson), Ret (rearranged during transfection), Trk-A, and
FGFR1 (fibroblast growth factor receptor 1) kinases [32]. In
this latter study, cell lines exposed to PHA-739358were found
to be sensitive to concentrations in the range 28 to 300 nM and
the mode of action of PHA-739358 corresponded to Aurora B
inhibition as assessed by phospho-histone H3(Ser10) inhibi-
tion. In addition, cells with tetraploid (4n) and polyploid (>4n)
DNA content were observed to accumulate upon treatment
with PHA-739358 [32]. Preclinical efficacy and toxicity stud-
ies were also performed in nude mice transplanted with sev-
eral human xenografts, employing maximum tolerated doses
(MTD) of 60mg/kg/day for 5 days, 30mg/kg/day for 10 days,
or 45 mg/kg/day for 10 days. Tumor growth inhibition (TGI)
was observed to be 66% to 98%; the compound was fairly
well tolerated with only mild weight loss and myelosuppres-
sion. PHA-739358 has also been tested in a rat model having
DMBA (9,10-Dimethylbenz-A-Anthracene) induced mam-
mary carcinomas. At 25 mg/kg, TGI was measured as 75%
and a complete cure was achieved in one rat [32]. Recently a
Phase I study results were reported. Pharmacokinetic profiles
were linear, and dose and time dependent. Of 80 patients
assessed, stable disease was observed in 28, and in seven
cases, this lasted for six months [33]. In another Phase I study,
56 patients divided into two parts (part 1 has 40 patients and
part 2 has 16 patients) received escalating doses (45, 90, 180,
360, 500, 580, 650 mg/m2: 24 h infusion every 14 days) of
PHA-739358 [34]. In part 1, patients received escalating
doses of PHA-739358 without the co-administration of
G-CSF (granulocyte stimulating factor). Doses were further
escalated in part 2 in the presence of G-CSF. The MTD estab-
lished in part 1 was 500 mg/m2. DLTs (dose limiting toxicity)
were reported in 6 patients, which include neutropenia, grade 4
mucositis, and neutropenic infection. In part 2, 16 patients
received the escalating doses of 500, 750, and 1000 mg/m2



























Compound, company, & code In vitro potency In vitro cellular
potency (IC50)     
Preclinical activity Clinical development
MLN8237, Milliennium [62] Aurora A(IC50) - 1 nM Pediatric cancer  
cell lines: Median 
IC50 is 61 nM 
Solid tumors and 
leukemias 
Phase II 
Advanced solid and blood cancers.  
Good pharmacokinetic profile
ENMD-2076, EntreMed [66] Aurora A(IC50) - 14 nM 25 - 700  nM Solid tumors & 
multiple myeloma. 
Induced 51% TGI  & 




Partial response in two platinum 
refractory ovarian cancer patients 
MK-5108, Vertex [68] Aurora A(IC50) – 0.064 nM 0.16-6.4 M Solid tumors. 58% TGI 
was achieved at 45 
mg/kg in SW48 
xenograft model 
Phase I 
Advanced and refractory solid tumors 
AZD1152, AstraZeneca [73,74] Aurora B(IC50) - 0.37 nM 3 - 40 nM 
(leukemia cell 
lines) 
Solid tumors &  AML Phase II 
Advanced solid and blood cancers. 
Overall 25% response rate. Stable 
disease in some patients 
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along with G-CSF. No severe DLTs in the presence of G-CSF
were reported even at maximum dose administered
(1000 mg/m2). The dose 1000 mg/m2 of PHA-739358 along
with G-CSF induced objective response in one refractory
small cell lung cancer patient. This is the first time that the
partial responses have been reported for an AKI with min-
imum toxicities. Several prolonged disease stabilizations
were also reported in part 1 schedule. Phase II and Phase








































PHA-680632, Nerviano [78] Aurora A(IC50) -   27 nM 
Aurora B(IC50) - 135 nM 
Aurora C(IC50) - 120 nM 
0.06 - 7.15 µM Solid tumors and 
leukemia. 85% 
TGI resulted in 
HL60 human 
xenograft model. 





VE-465, Merck [80] 
Aurora A(Ki) -    1 nM 
Aurora B(Ki) -  26  nM 
Aurora C(Ki) -  8.7 nM 
        - 







JNJ-7706621, Johnson [84] Aurora A(IC50)  - 11 nM 
Aurora B(IC50)  - 15 nM 






CCT129202, Chroma [85] Aurora A(IC50) - 42 nM
Aurora B(IC50)  - 198 nM 
GI50
0.08 - 1.7 µM  
Solid tumors. 
Induced TGI in 
HCT116  human 
xenograft model 
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III single agent studies without G-CSF are underway in 7
types of solid tumors [34]. However, G-CSF is also being
considered in further clinical studies. In addition to AKs,
PHA-739358 has been also shown to inhibit BCR-ABL
kinase (breakpoint cluster region-abelson) [35]. Many chronic
myeloid leukemia (CML) patients acquire resistance to the
BCR-ABL inhibitor imatinib by specific BCR-ABL muta-
tions, particularly the T315I gate-keeper mutation.
Interestingly, PHA-739358 inhibited both wild type BCR-
ABL (25 nM) and T315I mutated protein in kinase assays.
Moreover, PHA-739358 reportedly has a higher affinity for
the T315I form (5 nM) than the Abl wild type (21 nM) [35],
which may prove advantageous for clinical treatment. This
compound is currently in Phase II studies, being investigated
in imatinib-resistant CML patients [33]. Twelve CML patients
were enrolled and received doses from 250 to 400 mg/m2/day
Table 4 AKIs in early preclinical development and first generation AKIs
BubR1: Budding uninhibited by benzimidazoles 1 homolog beta  
Bub1: Budding uninhibited by benzimidazoles 1 
Cenp-E: Centromere protein E




Telik’s dual Aurora A & B inhibitor 
Structure not available [86] 
Inhibits Aurora A & B 
in 1-10 nM IC50 range 
15 - 500 nM Solid tumors and 
hematological cancers. 
72% TGI was achieved 
in HL60 xenograft    
AKI-001, Roche [87] Inhibits Aurora A  
& B at nanomolar 
concentrations 
>100 nM Solid tumors. 92% TGI  
achieved in HCT116 
xenograft 
Hesperadin, Boehringer Ingelheim 
[89]
Inhibits Aurora B at 
nanomolar range 
concentration 
      - Many mitotic functions 
of Aurora B were 
discovered using 
Hesperadin, including 
its role in chromosomes 
attachment  to mitotic 
spindle, conversion of 
monotelic to syntelic 
forms, and recruitment 
of   BubR1 and Bub1     
ZM447439, AstraZeneca [90] Aurora A(IC50)- 1 µM 
Aurora B(IC50) - 0.05µM 
       - Using ZM447439, 
Aurora B roles in  
recruitment of Cenp-E 
and BubR1 towards  
kinetochore, 
chromosome alignment 
and spindle check point 
regulations were     
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(3 consecutive weeks every 4 weeks). Two patients with
T315I BCR-ABL achieved complete hematological response.
One patient displayed complete cytogenetic and molecular
response after 3 months. PHA-739358 was well tolerated
and only grade 3/4 neutropenia has been reported. As part of
the pharmacodynamic study, CRKL phosphorylation was de-
creased in majority of treated patients. Additional studies in
CML resistant patients are underway [33].
CYC116
CYC116, discovered by Cyclacel Ltd., is an orally available
AKI that has been tested in a Phase I trial. CYC116 was
designed from the subset of lead N-phenyl-4-(thiazol-5-yl)
pyrimidin-2-amines through cell-based screening of kinase-
directed compound library [36]. The potency and specificity
of CYC116 to Aurora kinases A and B was rationalized using
X-ray crystal structure of the CDK2/CYC116 complex and
docking to Aurora A structural model; indeed, specific resi-
dues responsible for the (differential) activity were identified
[36]. It has been found to inhibit Aurora A, B, and C with
IC50 values of 44, 19, and 65 nM, respectively, and also
VEGFR2 (vascular endothelial growth factor receptor 2) with
an IC50 of 69 nM [37]. In this study, the proliferations of
various cancer cell lines with different genetic backgrounds
were inhibited with IC50 values of 34 to 1370 nM. CYC116 is
a targeted drug that has antimitotic and anti-angiogenesis
properties [36]. It was shown to inhibit autophosphorylation
of Aurora A and B in A549 lung cancer cell lines, demon-
strating its specificity against AKs, and it also induced failed
mitosis, resulting in polyploidy (Fig. 2), which eventually
killed the cells by apoptosis [36]. Further, CYC116 exhibited
antitumor activity in various leukemia, solid tumor xenograft
and leukemic syngenic models [36]. In mice with P388/D1
leukemia, it suppressed angiogenesis, decreased phosphoryla-
tion of histone H3, and induced accumulation of 4n and >4n
DNA in cells [37]. It was reported to significantly reduce
tumor neovascularization in a dose-dependent manner, possi-
bly due to inhibition of VEGFR2 [38]. In P388D1 mouse
leukemia model, at 45 and 67 mg/kg twice daily, the drug
increased the life span of 172% and 183%, respectively. Oral
administration of CYC116 in NCI-H460 xenograft, at 75 and
100 mg/kg for 5 days caused significant tumor growth delays.
Adverse side effects have not been reported. A Phase I trial in
advanced solid tumors has been conducted to determine its
MTD and evaluate its pharmacokinetic properties [36].
SNS-314
SNS-314 is a pan-Aurora kinase inhibitor discovered and
developed by Sunesis pharmaceuticals which has been tested
in a Phase I clinical trial. It was designed from the lead
molecule, 2-aminoethyl phenyl benzamide through structure-
activity optimizations. It has been reported to inhibit Aurora
A, B, and C with IC50s of 9, 31, and 3 nM, respectively [39].
Additionally, it was shown to inhibit 24 other kinases with
higher IC50 values. It inhibited cell proliferation in different
human cell lines with IC50 values of 1.8 to 24.4 nM, and
induced polyploidy. Histone H3 phosphorylation was signif-
icantly inhibited in all 6 cell lines tested with IC50 values 9–
60 nM. The anti-tumor activity of SNS-314 was tested in
several solid tumor xenograft models [39]. Preliminary in vivo
study to determine dosing and schedules was performed in
HCT116 xenograft. This study involved administration on a
biweekly schedule for three weeks and reported 54–91% TGI
at 170 mg/kg in breast, prostate, lung, ovarian, and melanoma
xenografts. Single dose of SNS-314, 50 or 100 mg/kg, led to
the complete inhibition of histone H3 phosphorylation as early
as 3 h after administration in HCT116 xenograft model. This
corresponded to the appearance of polyploid cells and
caspase-3 activation [39]. The drug has been subjected to a
Phase I clinical trial involving 32 advanced solid tumor
patients, divided into 8 cohorts with doses ranging from 30
to 1800 mg/m2 [40]. Only Grade 1 and 2 toxicities were
observed, suggesting it was well tolerated. A dose limiting
toxicity, namely neutropenia (Grade 3), was observed at a
dose of 1440 mg/m2. Plasma levels of SNS-314 were dose-
proportional and no drug accumulation was reported. Stable
disease has been reported in 6 patients with advanced solid
tumors [40].
a. HCT116 control cells            b. 48 h CYC116 treatment      c. 48 h ZM447439 treatment  Fig. 2 Confocal microscopic
images of HCT116 colorectal
cancer cells treated with
CYC116 and ZM447439. a)
DAPI (4′,6-diamidino-2-
phenylindole) staining of diploid
HCT116 parent cell line. b) & c)
CYC116 and ZM447439
treatments resulted in the
formation of polyploid cells
Invest New Drugs (2012) 30:2411–2432 2417
VX-680
VX-680 was discovered by Vertex Pharmaceuticals, Oxford,
UK. It was designed during the SAR exploitation of a lead
molecule amino pyrazole linked to 2-substituted quinazoline
[41]. It has been shown to inhibit Aurora A, B, and C with
Ki values of 0.7, 18, and 4.6 nM, respectively [42]. In
cytotoxicity assays with several tumor cell lines, VX-680
was reported to inhibit proliferation with IC50 values rang-
ing from 15 to 130 nM. It was also observed to disrupt
mitosis in a wide variety of tumor cell lines by affecting
chromosome segregation and cytokinesis, eventually induc-
ing the accumulation of cells with 4n DNA content, activat-
ing checkpoints, and subsequently inducing apoptosis [42].
Despite promising results, clinical trials involving this com-
pound were suspended due to its toxicity profile (one case of
heart failure). However, the compound has been tested in
patients with advanced CML, acute lymphoblastic leukemia
(ALL), and myelodysplastic syndromes because it has been
found to successfully inhibit the T315I mutated form of BCR-
ABL, which is resistant to imatinib. This surprising result
prompted a re-examination of other clinical compounds
against drug-resistant kinases. VX-680 has been observed to
bind to wild type BCR-ABLwith a dissociation constantKd of
~20 nM and to T315I (as well as other Abl mutants) with a Kd
of 5 nM. In vitro assays have shown that VX-680 inhibits the
activity of wild type BCR-ABL and BCR-ABL (T315I) with
IC50 values of 10 and 30 nM, respectively [43].
AT9283
AT9283 developed by Astex Therapeutics is the first AKI
discovered through the company’s proprietary fragment-
based screening approach. The pyrazole-benzimidazole hit
compound was improved by SAR to a lead. The lead optimi-
zation was guided by X-ray crystallography and finally
resulted in AT9283 as a clinical candidate [21]. It is currently
in several Phase II studies under the Cancer Research UK. It
has been shown to be an inhibitor of several kinases, including
Aurora A (3 nM), Aurora B (3 nM), JAK2 (janus kinase)
(1.2 nM), JAK3 (1.1 nM), and Abl (4.0 nM, T315I) [21].
HCT116 cells exposed to AT9283 exhibited polyploid pheno-
types, which are typically associatedwith predominant Aurora
B inhibition [21]. Like PH3-739358, AT9283 was found to
inhibit wild-type BCR-ABL and T315I BCR-ABL (IC50
values of 110 and 4 nM, respectively) [44]. AT9283 has also
been observed to inhibit proliferation of BaF3 cells with both
wild type BCR-ABL and T315I BCR-ABL (IC50 values of
13 and 11 nM, respectively). In cellular assays, it inhibited the
proliferation of BCR-ABL driven chronic myelogenous leu-
kemia (BaF3) cells as judged by the inhibition of CRKL
(v-crk sarcoma virus CT10 oncogene homolog (avian)-like)
phosphorylation. In vivo efficacy of AT9283 was tested in
BaF3 xenograft with either BCR-ABL wild type or T315I
mutation. At 12.5 mg/kg for 5 days, followed by 2-day drug
holiday AT2983 significantly inhibited tumor growth without
severe toxicities. It has also been found to induce significant
reductions of tumor volume in K562 (CML, BCR-ABL pos-
itive) xenograft mouse model at 12.5 mg/kg [44].
In one trial, skin punch biopsies were taken for subsequent
immunohistochemical studies from patients treated with
AT9283, as well as serum samples collected at regular inter-
vals. Inhibition of histone H3 phosphorylation, p53 stabiliza-
tion, reduction of PCNA and Ki67 were detected. Analysis of
the serum samples indicated elevation of M30 and M65
apoptotic markers and caspase activation [45]. The safety,
tolerability, and preliminary efficacy of this compound are
currently being evaluated in Phase I/II clinical studies. In
one study, 30 patients with different refractory leukemias were
enrolled for part of a Phase I trial. Patients were treated with
escalating doses of AT9283, rising from 3 to 162 mg/m2/day
[46]. No DLT was observed at doses below 72 mg/m2/day,
except in one patient who developed tumor lysis syndrome at
12 mg/m2/day. At the maximum administered dosage, two
DLTs and three deaths were reported, so further attention was
focused on sub-maximum doses. Commonly observed DLTs
included septicemia, pneumonia, and mucositis [46]. In a
second study, 40 patients (five cohorts) with refractory solid
tumors were enrolled as part of a second Phase I clinical study.
Patients were treated with escalating doses, rising from
1.5 to 12 mg/m2/day. No DLTs were observed at doses below
6 mg/m2/day. At 12 mg/m2/day, two patients developed fe-
brile neutropenia; 9 mg/m2/day was identified as the MTD. At
this dosage, 3% of patients showed a partial response and 30%
displayed stable disease [47].
R763
R763 (AS703569), which was discovered and developed by
Rigel, is an orally available Aurora inhibitor, currently in
Phase I study. It was designed and developed based on a
image-based phenotypic screen. It has been reported to
inhibit Aurora A, B, and C with IC50 values of 4, 4.8, and
6.8 nM, respectively and to inhibit Abl, FLT1 (fms-related
tyrosine kinase), and FLT3 oncogenic kinases [48]. In this
study, Colo205, MiaPaCa-2, HeLa, and MV4-11 cells were
observed to be most sensitive to R763 (IC5002 to 8 nM),
but primary proliferating cells were also sensitive despite
having higher IC50 values (IC50031 to 160 nM). This could
be due to slower cell proliferation and intact cell cycle check-
points. No effect was observed on non-dividing cells at the
highest concentration tested. R763 appeared to induce endor-
eduplication within 48 h as evidenced by the accumulation of
4n and 8n cells. Colo205, HeLa, and MiaPaCa-2 underwent
apoptosis after 48 h. In a preclinical phase, the in vivo efficacy
of R763was tested inMiaPaCa-2, adriamycin-resistant tumor,
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MOLT-4, and MV4-11 xenograft models. Significant reduc-
tion in tumor volumes did not occur in the MiaPaCa-2 xeno-
graft model, but histological regression and reduction in
histone H3 phosphorylation (Ser10) was observed. In con-
trast, tumor volumes were significantly reduced in
adriamycin-resistant tumors. Treatment of the MOLT-4 xeno-
graft model resulted in a 5–10% reduction in the total number
of bone marrow cells. The percentages of leukemia cells
were significantly reduced, whereas control groups were
not affected. In the MV4-11 xenograft, R763 induced
pronounced anticancer activity in a dose-dependent manner.
For a dose of 20 mg/kg/day, undetectable levels of
tumors were seen in 17% of animals. Increased life span was
observed in all treated groups, whereas all control mice
died early [48].
Two Phase I studies were completed and one study is
underway. Data from two studies were reported at interna-
tional meetings. Initial clinical studies have been performed
with two different dosing regimens to determine the com-
pound’s MTD, toxicity, and pharmacodynamic profile [49].
Cohorts of three patients were assigned to one of the two
regimens. The starting dose was 6 mg/m2 p.o. (Per Os) per
21-day cycle divided into two or three doses. Regimen 1
involved dosing on days 1 and 8, while regimen 2 involved
dosing on days 1, 2, and 3. 15 patients were enrolled,
including three with uterine, three with cervical, and two
with breast cancer. Initially, two cohorts of three patients
were treated at dose level 1, and no significant toxicity or
adverse side effects were observed. Two patients did not
receive effective treatment and one patient withdrew con-
sent. During this study, two patients received 4+ dosing
cycles and one received 3+. Overall, both dose levels (6
and 12 mg/mg2) were well tolerated [49]. Further dose
escalations were carried out in patients with hematological
malignancies in a second Phase I study [50]. Two dosing
regiments were tested: days 1–3 and 8–10 of a 21-day cycle
(regimen 1) and days 1–6 of a 21-day cycle (regimen 2). In
regimen 1, 24 patients were treated up to dose levels of
47 mg/m2. At the maximum dose of 47 mg/m2, two grade 3
diarrheas have been reported. In regiment 2, 21 patients
were also treated up to dose levels of 47 mg/m2. At this
dose two DLTs namely, one neutropenic infection and two
grade 4 mucositis have been reported. In this Phase I study,
the established MTD was 37 mg/m2. Other reported toxic-
ities include neutropenia, anemia, thrombocytopenia, and
gastrointestinal disorders. One patient with CML (T315I)
displayed hematological and cytogenetic response, one
CML patient had a partial response, three AML patients
achieved reduction in peripheral blasts, and several disease
stabilizations were also reported [50]. Further enrollment of
patients was ongoing at the time of report. Another Phase I
study of R763 in combination with gemcitabine in advanced
malignancies was recently completed.
PF-03814735
Pfizer’s PF-03814735 is another orally available dual
Aurora-A and Aurora-B inhibitor, which is currently in a
Phase I study. It was discovered by SAR exploitation of lead
pyrimidine scaffold. PF-03814735 was eventually designed
by SAR optimizations at C2 and C4 positions of pyrimidine
scaffold [51]. It has been found to inhibit recombinant
Aurora A and Aurora B with IC50 values of 5 and
0.8 nM, respectively, as well as FLT1, FAK (focal adhesion
kinase), TrkA, MET, and FGFR1 kinases at higher IC50
values [52]. It has also been shown to inhibit the prolifera-
tion of various human tumor cell lines (IC50042 to
150 nM). In this study, phosphorylation of Aurora B
(Thr232) was reduced significantly in MDA-MB-231, using
a concentration of PF-03814735 close to the IC50 (about
20 nM). It was also found to inhibit phosphorylation of
histone H3 (Ser10) with an IC50 value of ~50 nM. Aurora
A autophosphorylation (Thr288) was also inhibited at an
IC50 value of ~150 nM, which is 3-folds higher than histone
H3 (Ser10) phosphorylation inhibiton. PF-03814735 was
shown to inhibit Aurora A and Aurora B rapidly and revers-
ibly in cell cultures. When HCT116 cells were treated with
PF-03814735, initially 4n DNA content cells accumulated
followed by ≥8n DNA content, consistent with failed mito-
sis. At similar concentrations, inhibition of phospho-histone
H3 was observed in athymic mice bearing HCT116 xeno-
graft. Mice bearing HCT116 tumors were treated once daily
with 10, 20, or 30 mg/kg for 10 days. Significant tumor
growth inhibition (≥50%) occurred at ≥20 mg/kg. Moreover,
significant antitumor efficacy was observed when PF-
03814735 was tested in A2780, MDA-MB-231, Colo-205,
and HL-60 xenograft models. Mice xenograft models toler-
ated various dosing schedules with very few toxic effects
[52]. In Phase I initial clinical study, 57 patients with solid
tumors were treated [53]. In schedule A, 32 patients re-
ceived 5–100 mg/day for 5 days; or in schedule B patients
(25) received 40–60 mg/day for 10 days of 21-day cycles.
The MTD for schedule A was 80 mg/day. One patient in
schedule A experienced grade 3 proctalgia and two patients
experienced grade 3 and grade 4 febrile neutropenia. TheMTD
for schedule B is 50 mg, where two patients experienced grade
3 increase of aspartate aminotransferase and grade 2 ventricu-
lar dysfunction. PF-03814735 was rapidly absorbed, appeared
in circulation within 6 h of dosing, and it exhibited favorable
linear pharmacokinetics. Pharmacodynamics of PH-03814735
was evaluated using phospho-histone H3 (Ser10) staining of
mitotic cells as a surrogate biomarker. In comparison to the
baseline, phospho-histone H3 levels decreased in 10
patients and paradoxically increased in two treated patients.
In terms of efficacy, 19 patients achieved stable disease.
Moreover in schedule A, five patients with stable disease
displayed low tumor shrinkage [53].
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GSK1070916
GlaxoSmithKline’s GSK1070916 is a reversible Aurora B
and C inhibitor that is currently studied by Cancer Research
UK in a Phase I clinical study. It was designed from the
various SAR refinements of a lead 7-azaindole series [54]. It
has been shown to inhibit Aurora B-INCENP and Aurora C-
INCENP with IC50 values of 3.5 and 6.5 nM, respectively,
and to cross-react with FLT1, TIE2 (tyrosine kinase with
immunoglobulin-like and EGF-like domains 1), SIK (salt
inducible kinase), FLT4, and FGFR1 at higher concentrations
[55]. The in vitro activity of GSK1070916 has been tested on
161 tumor cell lines and found to inhibit the proliferation of
cancer cell lines with a median IC50 of 8 nM [56]. It did not
show any potent anticancer effects on non-proliferating
HUVEC cells (IC5003900 nM). In A549 cell line, it in-
duced polyploidy and apoptosis in a dose dependent man-
ner, which is consistent with Aurora B inhibition.
Apoptotic cell death was evidenced by induction of
caspase-3 and PARP cleavage in Colo205 cells. In vivo
efficacy was tested in several xenograft models at 25, 50,
or 100 mg/kg once daily for five consecutive days, fol-
lowed by two days off, for two or three cycles. Complete
or partial regressions were achieved in A549, HCT116,
HL60, and K562 xenograft models and stable disease was
observed in Colo205, H460, and MCF-7 xenografts. Ad-
verse toxicities were not reported for this compound. Its
efficacy was also tested in two human leukemia models:
MV-4-11 and HL60. Significant dose-dependent increase
in median survival times were reported [56]. GSK1070916
Phase I clinical study is currently recruiting patients with
advanced solid tumors.
AMG-900
Amgens’s AMG-900 is an orally available pan-Aurora ki-
nase inhibitor that is currently in Phase I clinical studies. It
has been shown to inhibit Aurora A, B, and C with IC50
values of 5, 4, and 1 nM, respectively [57]. It has also been
shown to cross-react with other kinases including p38α,
TYK2 (tyrosine kinase 2), JNK2, MET, and TIE2 with
IC50 values in the range of 53–650 nM. It has been found
to inhibit the proliferation of 26 diverse cancer cell lines
with IC50 values between 0.7–5.3 nM. Interestingly it was
able to overcome the resistance in PgP (P-glycoprotein)
expressing multidrug resistant cancer cell lines, as it
inhibited colony formation of resistant and parent cell lines
uniformly. Strikingly other AKIs (AZD1152, VX-680,
PHA-739358) were less potent than AMG-900, when
tested on these multidrug resistant cell lines. Moreover,
the compound was also shown to inhibit AZD1152 resis-
tant HCT116 cell line harboring Aurora B mutation
(W221L). AMG-900 inhibited both parent and AZD1152
HCT116 resistant cell lines with equal potencies in colony
formation assay [57], while human foreskin fibroblasts
were relatively insensitive to the drug. However, it in-
duced cell death in proliferating human bone marrow
mononuclear cells at nanomolar concentrations, suggesting
its high activity in cycling cells. AMG-900 inhibited auto-
phosphorylation of Aurora A (Thr288) and histone H3
phosphorylation (Ser10) in a dose-dependent manner, with
IC50 values of 6.5 and 8.2 nM, respectively. AMG-900
predominantly showed Aurora B inhibition phenotype, as
evidenced by the appearance of polyploid HeLa cells due
to failed cytokinesis. Appearance of polyploid cells corre-
sponded to the induction of p53 and p21 levels, which are
widely accepted biomarkers related to Aurora inhibition.
The compound induced time-dependent induction of apo-
ptosis, as evidenced by the increase in the caspase-7 levels
over the period of time. In HCT116 xenograft model it
inhibited histone H3 phosphorylation in a dose-dependent
manner. As expected it also suppressed histone H3 phos-
phorylation in mouse bone marrow cells. Treatment of
mice with AMG-900 at 3.75, 7.5, and 15 mg/kg/twice
daily for 2 consecutive days/week/3 weeks resulted in
dose-dependent TGI’s in the range 40 to 75%. Toxicities
reported include moderate weight lose and myelosuppres-
sion. Dose-dependent TGI’s were also reported in an
alternate daily dosing schedule. It has also been tested in
other xenograft models and 3 multidrug resistant (MDR)
xenograft models. Two schedules were employed for this
study. The xenografts were treated at 15 mg/kg b.i.d/2
consecutive days/week or 3 mg/kg b.i.d/day. AMG-900
exhibited significant antitumor activity (50–97% TGI) in
all the xenografts models including MDR xenografts. It
was able to overcome the drug resistance of MDR xeno-
grafts, otherwise insensitive to docetaxel or paclitaxel at
their respective MTDs. Importantly, inhibition of histone
H3 phosphorylation correlated with plasma drug concen-
trations [57]. Overall AMG-900 displayed favorable phar-
macokinetic and pharmacodynamic profiles with
anticipated minimum toxicities. Importantly, AMG-900
has great potential to overcome both the tumor multidrug
resistance and to show activity in cancers resistant to other
AKI due to mutation of the Aurora kinase B binding site.
Currently two Phase I studies are underway in patients
with advanced solid tumors and acute leukemias.
Aurora A inhibitors in clinical trials
MLN8237
MLN8237 (Alisertib) discovered by Millennium phar-
maceuticals has been reported to be a highly specific
and potent inhibitor of Aurora A (IC5001 nM) [58].
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This is a second generation Aurora A inhibitor from
this company, as the predecessor to MLN8054.
MLN8054 was terminated in Phase I studies due to
off-target toxicities observed. This led to the develop-
ment of new Aurora A specific inhibitor by the com-
pany, with a code name, MLN8237. MLN8237 was
designed through SAR optimization of lead 5-
H-pyrimido[5,4-d][2]benzazepine. It is currently in nu-
merous Phase II clinical studies. It does not appear to
have any significant off-target effects towards other
kinases included in the panel, but it has been shown
to inhibit wild-type BCR-ABL and T315I BCR-ABL
effectively in both kinase assays and in vitro cell cul-
tures [59]. It has also been found to inhibit growth in
HCT116, PC3, SK-OV-3, and LY-3 cancer cells lines in
cell proliferation assays, with GI50 values between 16
and 469 nM [58]. The specificity of MLN8237 has
been tested in multiple myeloma (MM) cell lines [60].
In this study, autophosphorylation of Aurora A (Thr
288) was markedly inhibited at 0.5 μM in MM cell
lines. MLN8247 induced 2 to 6-fold accumulation of
G2/M followed by apoptosis, as evidenced by cleavage
of PARP, caspase-9, and caspase-3. In addition, cell
death by senescence was predominant after long expo-
sure of MM cell lines. The efficacy of MLN8237 was
tested in vivo in a MM xenograft model implanted in
SCID (severe combined immune deficiency) mice. Tu-
mor volumes were found to be significantly reduced at
30 mg/kg, and TGI was determined to be 42% and
80% at 15 and 30 mg/kg, respectively. Further, the
overall survival rates of animals were significantly pro-
longed [60]. MLN8237 has also been tested on many
pediatric cancer cell lines including rhabdomyosarcoma,
Ewing sarcoma, glioblastoma, neuroblastoma, ALL, and
AML [61]. In this study, the median IC50 was reported as
61 nM, ALL cell lines displaying the highest sensitivity and
rhabdomyosarcoma cell lines were the least sensitive. Disease-
free survival was improved in 80% of solid tumor models and
100% in ALL models, even more promising, a sustained
complete response was achieved in 3 of 7 neuroblastoma
models and the activity was much higher than standard anti-
cancer agents [61]. Phase I dose escalation and dose-limiting
toxicity studies involving cohorts of three patients with ad-
vanced solid tumors have been completed [62]. Each patient
was given an oral dose once per day for seven days in a 21-day
cycles, with the dosage increasing from 5 to 150 mg/day until
DLTs were observed in more than two patients. DLTs were not
reported for doses of 5–80 mg/day. However, in some patients
mixed DLTs were reported at 150 mg/day, including G3 and 4
neutropenia, G3 somnolence, G3 mucositis or oral candidiasis,
confusion, agitation, and alopecia. Aurora A kinase inhibition
was inferred from the accumulation of mitotic cells in skin and
tumor biopsies [62]. Plasma levels of MLN8237 were found to
be dose-proportional, suggesting MLN8237 has a good phar-
macokinetic profile. Currently multiple Phase II MLN8237
studies are recruiting patients with a wide range of solid
cancers and blood cancers for optimal dosing regimen,
efficacy, and MTD determination.
ENMD-2076
EntreMed’s ENMD-2076, currently in Phase II clinical tri-
als, has been shown to selectively inhibit Aurora A with an
IC50 of 14 nM measured in biochemical assays [63]. The
molecule was designed by SAR optimization of a lead
imidazole-vinyl-pyrimidine scaffold. It was also found to
inhibit multiple oncogenic kinases, namely FLT3 (3 nM),
Src (sarcoma) (20 nM), VEGFR2 (36 nM), and FGFR1
(93 nM), as well as the growth of various cancer cell lines
(IC50025 to 700 nM) [63]. It was observed that 5 μM
ENMD-2076 induced G2/M arrest in HCT116 cells consis-
tent with Aurora A inhibition, rapidly inducing apoptosis.
Recently, ENMD-2076 has also been shown to be highly
effective against MM cell lines and primary MM cells
derived from patients [64]. In this study, ENMD-2076 was
found to cause 50% cell death in MM cell lines at a con-
centration of 3 μM for 72 h of exposure. It also induced
apoptotic cell death after only 6 h of exposure as evidenced
by annexin-V staining, PARP cleavage, and activation of
caspase-9, 8, and 3. In MM cells it significantly reduced
autophosphorylation of Aurora A (Thr288) after 24 h of
exposure. However, it also inhibited Aurora B at concen-
trations that resulted in cell death, as shown by down-
regulation of histone H3 phosphorylation (Ser10). The in
vivo efficacy was tested in a H929 human plasmocytoma
xenograft model at doses of 50, 100, and 200 mg/kg. A
dose-dependent efficacy was observed in all animals and
maximum affect was achieved at 200 mg/kg with good
tolerability. Immunohistochemistry on sacrificed animals
revealed reduced Ki67 levels, increased caspase-3 levels,
and decreased phospho-histone levels in treated animals
compared to an untreated control [64]. When a HT-29
xenograft model was dosed at 100 or 200 mg/kg once per
day, the tumor volumes remained static until around 17 days,
and moderate regression was subsequently observed for
200 mg/kg. Immunohistochemistry revealed there was a
corresponding reduction in Ki67 levels. ENMD-2076 has
also been tested in a patient-derived colorectal cancer (CRC)
xenograft where it was found to induce TGI in all cases (K-ras
mutant) [65]. In the MDA-MB-231 mouse xenograft model,
ENMD-2076 has been observed to reduce tumor growth by
51% at a dose of 50 mg/kg per day and to cause tumors to
regress by 70% at a dose of 200 mg/kg [63]. Recently, Phase I
study results were reported including pharmacokinetic, phar-
macodynamic, and antitumor activity profiles. Patients with
refractory advanced solid tumors were treated with continuous
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oral daily dosing. Doses in the range 60 to 200 mg/m2 were
tested in a standard 3+3 design. Totally 67 patients were
enrolled for this study [66]. At 200 mg/m2, two patients
displayed grade 3 hypertension and 160 mg was reported as
MTD. ENMD-2076 has linear pharmacokinetic profile and
displayed significant antitumor activity including decreased
VEGFR2 levels in plasma. The highest activity was reported
in ovarian cancers, where two patients with platinum refrac-
tory disease showed partial responses [66]. Three Phase I
studies are currently underway being tested in advanced solid
tumors and multiple myeloma.
MK-5108
MK-5108 (VX689), discovered and developed by Ver-
tex Pharmaceuticals, has been studied in a Phase I
clinical trial in patients with advanced solid tumors. It
has been shown to inhibit Aurora A with an IC50 value
of 0.064 nM [67]. It also inhibited Aurora B and
Aurora C at higher IC50 values (220 and 190 folds
higher than Aurora A). It has been shown to inhibit the
proliferation of 17 diverse cancer cell lines with IC50
values ranging from 0.16 to 6.4 μM. MK-5108 signif-
icantly enhanced the efficacy of docetaxel in HeLa-S3
and ES-2 cell lines. MK-5018 and docetaxel combina-
tion also showed similar efficacy in HeLa-luc and ES-2
xenograft models. In cell lines it predominantly showed
Aurora A inhibition phenotype (G2/M arrest), as his-
tone H3 phosphorylation was not inhibited, which is a
marker for Aurora B inhibition. MK-5108 inhibited
Aurora A, as also evidenced by the inhibition of Au-
rora A autophosphorylation (Thr288). MK-5108 in-
duced greater accumulation of phospho-histone H3 at
much lower concentrations compared to MLN8054, a
well known Aurora A specific inhibitor [67]. In vivo
efficacy of MK-5108 was tested in HCT116 and SW48
xenograft models. Doses of 15 and 30 mg/kg were
administered twice daily for 12 days. MK-5108 treat-
ment resulted in TGI’s of 10% and 17% at doses
15 mg/kg and 30 mg/kg, respectively in HCT116 xe-
nograft model. In SW48 xenograft model, intermittent
doses (twice daily/2 days/week/3 weeks) of 15 mg/kg
and 45 mg/kg resulted in 35% and 58% TGI’s, respec-
tively. MK-5108 was well tolerated and adverse toxic-
ities were not reported.
MK-5108 was tested in patients with advanced solid
tumors either as a single agent or in combination with doce-
taxel. Febrile neutropenia and myelotoxicity were reported as
DLTs in the combination treatment regimen. However, no
significant toxicities were reported in the monotherapy arm.
Disease stabilization was reported in 32% patients from both
arms and partial responses were reported in 12% of patients
only from the combination arm [68].
Aurora B inhibitors in clinical trials
AZD1152
AZD1152 (Barasertib) is an AstraZeneca compound which
has been shown to be a highly specific inhibitor of Aurora B
(0.37 nM) [69], and is currently in Phase II clinical studies.
It was designed and developed from the lead pyrazole-
acetanilide-substituted quinazoline by SAR exploitation
[70]. It has been found to exhibit varying potency across
different types of leukemia cells (ALL, PALL-2, MOLM13,
MV4-11) inhibiting their proliferation with IC50s ranging
from 3 to 40 nM, and also inhibits the proliferation of
freshly isolated patient leukemia cells (IC5003 nM). In this
work, exposure of MOLM13 and PALL-2 to AZD1152
resulted in accumulation of 4n/8n DNA cells, which subse-
quently underwent apoptotic cell death as demonstrated by
annexin-V staining [69]. In SW620 colon cancer cells, it has
been observed to inhibit the phosphorylation of histone H3
in a dose-dependent manner, which is indicative of Aurora
B inhibition [71]. Furthermore, it caused potent dose-
dependent growth inhibition of human xenograft models in
nude mice, including SW620, HCT116, Colo205, A549,
Calu-6, and HL-60. In these experiments, the extent of
growth inhibition ranged from 55 to 100%; the HL-60
model was the most responsive (complete regression was
observed). Elevated caspase-3 levels were observed in all
tumors isolated for histological assessment. The mechanism
of AZD1152 action was found to be similar in both in vitro
and in vivo conditions. AZD1152 was well-tolerated at
doses required for efficacy; myelosuppression is the primary
problem associated with high doses [71]. Treatment of the
human MOLM13 xenograft immunodeficient murine model
with AZD1152 at a dose of 25 mg/kg per day caused
significant reductions in tumor weight and growth [69].
However, none of the mice showed any signs of side effects,
which suggest that it was well tolerated.
Initial clinical study was conducted on 13 patients having
colon cancer, melanoma or some other solid tumors. The
compound was administered via intravenous (i.v.) infusion
(2 hrs per week) in a dose-escalating manner (100–450 mg)
on days 1, 8 and 15 of a 28-day cycle. Doses up to 300 mg
were well tolerated, but neutropenia was observed in three
patients at 450 mg. Significant disease stabilization was
observed in progressive cancers [72]. AZD1152 recently
entered Phase I/II clinical trials focusing on its safety, toler-
ability, pharmacokinetics, and efficacy profiles in AML
patients [73]. Treatment of AML patients was performed
in two parts; in part A, 32 individuals were treated (contin-
uous 7-day infusion every 21 days) at doses ranging from 50
to 1600 mg. Grade 3/4 stomatitis or mucosal inflammation
were reported as DLTs at doses ranging from 800 to
1600 mg. Most of the toxicities resolved following dose
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delay and no treatment related deaths have been reported.
This part of the study established MTD as 1200 mg. Con-
sequently, another 32 patients received 1200 mg in part B of
the study. For combined part A and part B, the overall
response rate was 25% in both newly diagnosed and re-
lapsed AML patients. The pharmacokinetic profiles were
favorable as assessed by the AZD1152 blood levels and
distribution to tissues [73]. Recently, barasertib has been
tested in patients with advanced solid malignancies using
escalating doses from 100 mg to 650 mg per day [74]. In
schedule A, 2 h i.v. infusion was given for every 7 days
across four escalating doses (100, 200, 300, and 450 mg). In
schedule B, the drug was administered every 14 days across
five escalating doses (200, 300, 450, 550, and 650 mg).
Schedule A included 19 patients and schedule B included
40 patients. Doses 250 mg and 400 mg per day were the
MTDs in schedules A and B, respectively. Neutropenia and
leukopenia were the most common side effects. Objective
antitumor effects were not observed, however, stable disease
achieved in 15 patients overall. In this study, the linear
pharmacokinetics has also been reported, as the systemic
exposure to AZD1152-HPQA (active drug) was observed
by 1 h into the infusion [74]. Currently AZD1152 is being
tested in a Phase II trial in large B-cell lymphoma patients.
BI 811283
Boehringer-Ingelheim’s BI 811283 is a Aurora B inhibitor
that is currently in a Phase II clinical study. It has been
shown to inhibit Aurora B with IC50 value of 9 nM and
also inhibited the proliferation of 24 diverse cancer cell lines
with an IC50 value <14 nM [75]. Chemical structure of BI
811283 is not disclosed by the company. Treatment of
cancer cell lines with BI 811283 resulted in polyploidy
within 48 h due to failed mitosis. It dominantly induced
senescence (based on SA-beta-GAL staining) within 96 h
and only 7% cells showed apoptotic phenotype (PARP
cleavage and nuclear fragmentation) after 96 h. In vivo
efficacy of BI 811283 was tested in NSCLC and colorectal
cancer cell line xenograft models. The compound was ad-
ministered once weekly by 24 hs.c. infusion. It inhibited
tumor growth of xenografts in dose-dependent manner and
at the MTD (20 mg/kg), tumor regression was reported in
some animals. Accumulation of lager and multinucleate
cells were reported, which is consistent with the Aurora B
inhibition phenotype [75].
In Phase I dose escalation study, BI 811283 has been
tested in advanced and metastatic solid tumors [76]. Patients
were randomized into two schedule treatment groups, q2w
and q3w in a bicentric Phase I dose escalation. In 3-week
treatment schedule, patients were treated with BI 811283 as
24 h i.v. infusion on day 1 of each 21-day treatment cycle.
The MTD was reported to be 230 mg/kg. The main side
effects include reversible hematotoxicity, neutropenia, and
febrile neutropenia. However, accumulated toxicity was not
reported in two patients that are treated for >16 courses. As
part of the efficacy, stable disease was reported in 33.3% of
patients [76]. In another 4-week treatment schedule, patients
received BI 811283 (5–140 mg/kg) as 24 h i.v. infusion on
days 1 and 15 of each treatment cycle [77]. The MTD was
reported to be 140 mg/kg. The dose limiting toxicities were
almost identical to previous schedule. Stable disease was
reported in 29% of patients. Pharmacokinetic profiles were
near-linear and the half-life was 11.9 to 26 h. Additonal
dosing schedules in expanded patient cohorts were also
completed. However, the results are not yet published. A
Phase II clinical study in combination with cytarabine is
currently underway.
AKIs in advanced preclinical studies
PHA-680632
PHA-680632 is another pan-Aurora kinase inhibitor from
Nerviano. It emerged from SAR modifications of several
pyrrolopyrazole core sub-classes of ATP-mimetic pharma-
cophores [27]. It has been reported to inhibit Aurora A, B,
and C with IC50 values of 27, 135, and 120 nM, respec-
tively, and to cross-react with FGFR1 (IC500390 nM) [78].
It has also been shown to inhibit proliferation of various
cancer cell lines with different genetic backgrounds (IC500
0.06 to 7.15 μM). Further, this study found that PHA-
680632 selectively generated polyploidy in a cancer cell
line—HCT116, but not in a normal cell line. Treatment of
cells with anti-Aurora A siRNA, but not anti-Aurora B
siRNA induced accumulation of active caspase 9 and 3.
Similarly PHA-680632 induced accumualtion of active cas-
pase 9 and 3, which is an indicative of predominant Aurora
A inhibition related apoptosis. Treatment of HeLa cells with
2 μM PHA-680632 for 24 h resulted in dramatic down-
regulation of phospho histone H3 (Ser10). Its efficacy and
toxicity were tested in human tumor xenograft models, and
in mouse and rat syngenic models. These tests involved
administration of PHA-680632 at a dose of 45 mg/kg for
five consecutive days to mice bearing the HL60 tumor and
resulted in a TGI of 85% compared to tumor growth in
control animals treated only with the vehicle. Similar effects
were observed in A2780 and HCT116 models. In A2780
mouse xenograft model, inhibition of histone H3 phosphor-
ylation was observed within 8 h of dosing at 60 mg/kg. No
toxicities were reported at any of the doses employed [78].
Treatment of HCT116p53-/- cells with PHA-680632 after
ionising radiation exposure (IR) has been shown to result in
enhanced cell killing (with additive effect) as determined by
annexin-V staining, micronuclei and BRCA-1 foci
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formation. Correspondingly, combined treatment of IR and
PHA-680632 in HCT116p53-/- mice xenograft model
showed enhanced tumor growth delay [79].
VE-465
VE-465 is another pan-Aurora kinase inhibitor discovered
by Vertex pharmaceuticals. The chemical structure is similar
to that of VX-680. VE-465 was designed by SAR optimi-
zation of the lead amino pyrazole. Using ATP (adenosine
triphosphate) competitive binding assays it has been shown
to inhibit Aurora A, B, and C with Ki values of 1, 26, and
8.7 nM, respectively [80]. In preclinical studies it exhibited
anticancer effects on two hepatocellular carcinomas, Huh-7
and HepG2. It also suppressed Aurora B activity in a dose-
dependent manner within 1 h treatment of both cell lines.
Immunocytochemistry studies in Huh-7 and HepG2 using
anti α-tubulin and DAPI indicated that VE-465 causes the
formation of abnormal prometaphase cells, affecting centro-
some maturation and spindle bipolarity. These effects are
entirely consistent with inhibition of Aurora A in the treated
cells. VE-465 also induced mitotic abnormalities associated
with Aurora B inhibition, namely dispersal of the chromo-
somes. It induced endoreduplication and cell cycle arrest as
early as 24 h. At slightly higher concentrations, VE-465
induced apoptotic cell death in both Huh-7 and HepG2, as
measured by annexin-V staining [80]. It has also been
shown to have significant activity against paclitaxel-
resistant ovarian carcinoma at higher doses, causing an 8-
fold increase in apoptotic cell death at 100 nM [81]. Recent-
ly it was demonstrated to have significant activity against a
panel of resistant and non-resistant multiple myeloma cell
lines [82]. In this study, VE-465 inhibited proliferation of
MM cells at concentrations of 400 nM or less. G2/M, 8n,
and sub G1 populations were observed to accumulate with
increasing exposure time, and correspondingly apoptotic
markers appeared, including cleavage of PARP, caspase-3,
8, and 9. However, primary MM cells from patients are
relatively insensitive to VE-465. Further it was shown that
the effects of VE-465 were additive alongside with anti-MM
agents [82]. In vivo efficacy was tested in Huh-7 xenograft
model at 15, 25, and 35 mg/kg doses, administered twice
daily for 14 days. These treatments caused reductions in the
mean tumor volume of 59%, 59%, and 77% respectively
[80]. In this study, VE-465 was also observed to inhibit
histone H3 phosphorylation and to induce apoptosis in the
tumors in a dose-dependent manner.
JNJ-7706621
Johnson & Johnson’s JNJ-7706621 is an Aurora A and B
kinase inhibitor. It was designed by the refinement of a series
of acyl-substituted 1,2,4-triazole-3,5-diamine analogues [83].
The molecule has been reported to inhibit Aurora A and B
with IC50 values of 0.011 and 0.015 μM, respectively [84].
However, in this study, it was also shown to inhibit CDK1
(cyclin dependent kinases), CDK2, CDK3, CDK4, and CDK6
(IC5000.009 to 0.175 μM). Further, it inhibited proliferation
of various cancer cell lines (IC5000.112 to 0.514 μM), but
showed less potency against normal cell lines, which were
several-fold less sensitive. Moreover, it inhibited cell prolifer-
ation of both drug-sensitive and drug-resistant MES-SA cell
lines at almost identical IC50 values, suggesting that PgP
expression has no effect on JNJ-7706621 activity. Long-term
effects of this compound on cell proliferation were determined
by colony formation assay. HeLa cells were treated with
either 1 μM or 3 μM concentrations for 48 h, followed
by removal of the compound, and cells were then mon-
itored for 7 days. Colony formation inhibition of 55%
(1 μM) and 95.5% (3 μM) compared to control cells
was reported. JNJ-7706621 induced apoptosis in the
U937 histiocytic lymphoma cell line in a dose- and
time-dependent manner, as evaluated by annexin-V
staining. It also induced G2/M cell cycle arrest and
polyploidy, which is one of the major phenotypic
responses associated with Aurora kinase inhibition. The
compound inhibited histone H3 phosphorylation at con-
centrations of 1 to 4 μM, which is again consistent with
activity against Aurora B. The compound has been
subjected to preclinical in vivo testing using the A375
human melanoma xenograft model, at doses of 100 and
125 mg/kg. Although daily dosing was the most effi-
cient, five out of six test animals died after 22 days of
treatment. However, an alternative ‘7 days on, 7 days
off’ dosing schedule resulted in 93% TGI with no
treatment-related deaths [84].
CCT129202
Chroma’s CCT129202 has been shown to have high activity
against Aurora A and Aurora B. It was developed through
SAR optimization of an imidazopyridine scaffold. The com-
pound has been reported to inhibit Aurora A, B, and C with
IC50 values of 0.042, 0.198, and 0.027 nM, respectively [85].
It was also shown to cross-react with FGFR3, PDGFRβ
(platelet-derived growth factor receptor), and GSK3β (glyco-
gen synthase kinase 3 beta) at high concentrations. The effect
of this compound on cancer cell line proliferation was tested
on Colo205, SW620, HCT116, HT29, KW12, HeLa, A2780,
OVCAR8, MDA-MB-157, and MV4-11 cells, and was found
to have a half-maximal growth inhibition concentration
(GI50) in the range 0.08 to 1.7 μM. In preclinical studies, it
induced the accumulation of HCT116 cells with ≥4 N DNA
content, accompanied by the appearance of subG1 apopto-
tic cells and accumulation of PARP cleavage. In HCT116
colon carcinoma cells, CCT129202 inhibited histone H3
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phosphorylation after 15 min of treatment. The same effect
was observed in the HCT116 xenograft model, i.e., inhi-
bition of histone H3 phosphorylation after 15 minutes at a
dose of 100 mg/kg. Furthermore, it induced stabilization
of p53 (consistent with Aurora A inhibition). CCT129202
was administered at a dose of 100 mg/kg once a day for
9 days to HCT116 colon tumor xenografts in athymic
mice to test its effects on TGI. The compound was well
tolerated and induced significant TGI. Studies in mice also
indicated that the compound has a favorable pharmacoki-
netic profile [85].
AKIs in early preclinical studies
Telik’s dual AKIs
Telik’s Aurora A and B inhibitors are at early preclinical stage.
Telik’s Aurora inhibitors were designed by using proprietary
drug discovery technology called TRAP (Target-Related
Affinity Profiling). They have been reported to inhibit
Aurora A, B, and VEGFR2 with IC50s of 1–10 nM [86].
Telik’s compounds have also been shown to inhibit prolifera-
tion of various colon, leukemia, lung, pancreatic, ovarian, and
prostate cancer cell lines, with IC50s in the range 15 to
500 nM. Mechanistic actions consistent with Aurora inhibi-
tion were observed, including inhibition of histone H3 phos-
phorylation and polyploidy. The in vivo activity of
TLK60404, one of Telik’s specific AKI was tested in human
HCT116 and HL-60 mouse xenograft models. No toxicity or
drug-related weight loss was observed. In addition, tumor
growth was inhibited by 72% in HL-60 human xenograft
model [86].
AKI-001
Roche’s AKI-001 is an inhibitor of Aurora A and Aurora B
that is in initial preclinical studies. AKI-001’s core, the pyr-
idinyl pyrimidine amide scaffold, was discovered by high-
throughput screening against Aurora-A kinase [87]. Further
optimization and inclusion of lactam ring and hydrocarbon
constraint to pentacyclic scaffold led to the discovery of the
highly potent AKI-001 which is orally bioavailable phthala-
zine derivative with improved enzyme and cellular activity
and a high level of kinase selectivity. AKI-001 has been
shown to inhibit recombinant Aurora A and Aurora B at low
nanomolar concentrations in ATP-competition assays. The
compound also inhibited the proliferation of various cancer
cell lines with IC50 values below 100 nM. In cellular assays,
both Aurora A and Aurora B inhibition phenotypes were
reported. AKI-001 had good oral bioavailability and was
well tolerated at 5 mg/kg daily in the HCT116 xenograft
model. At this dose AKI-001 induced 92% inhibition of
tumor growth [87].
CHR-3520
After screening many small molecule inhibitors, Chroma
Therapeutics selected CHR-3520 for entry into preclinical
studies. Initial studies have indicated that CHR-3520 is an
inhibitor of AKs and other kinases related to cancer. Details
of the specificity and cellular potency of CHR-3520 in
relation to the AKs have not yet been disclosed [88].
Other AKIs
In addition to these compounds, many biotechnology and
pharmaceutical companies are developing novel AKIs. Cetek
selected CTK110, an AKI with promising in vitro and in vivo
anticancer activity, from a series of potential compounds.
Ambit Biosciences have used their KinomeScan technology
to select a lead AKI. KinomeScan is a novel and highly
promising chemogenomics-based technique that is able to




Hesperadin is the first generation AKI discovered by
Boehringer Ingelheim. Treatment of cancer cell lines with
hesperadin resulted in Aurora B inhibition phenotype.
The specificity of hesperadin towards Aurora A and C
is unknown. Most of the basic functions of Aurora B in
mitosis and its role in cancer cell proliferation were
discovered by inhibiting it with Hesperadin [89].
ZM447439
ZM447439, discovered by AstraZeneca, was the first AKI
to be thoroughly characterized [90]. ZM447439 has been
used extensively to study the biology of AKs and in their
validation as targets for anti-cancer drug development.
Natural AKI
Jadomycin-B
Discovery of Jadomycin B (an Aurora B inhibitor) is attributed
to structure-based virtual screening. Virtual screening against
Aurora B (PDB code 2BFY) resulted in 22 compounds
amongst a database of nearly 15,000 microbial natural
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products among which Jadomycin showed dose-dependent
inhibition of Aurora B and several human cancer cell lines
[25].
Drug resistance to AKIs
Over the last 15 years, cancer chemotherapy has been greatly
improved by the discovery of targeted drugs. In particular,
some targeted drugs have achieved complete cures in some
patients. However, the primary drug resistance or its devel-
opment after few courses of chemotherapy is a major obstacle
in the clinic. Many drug discovery companies are now focus-
ing on drug resistance after realizing its importance in clinical
rials and the clinic. Studies of drug-induced resistance in
cell line models in parallel with preclinical development
can be expected to yield significant information, and the
findings of such studies can be used to circumvent drug
resistance in clinical studies by designing combinations of
anticancer agents.
Until recently, very little was known about drug-induced
resistance mechanisms towards AKIs. One study found that
SW620 (colon carcinoma) andMiaPaca (pancreatic carcinoma)
cell lines became resistant to 1 μM AZD1152 over the course
of three months exposure [91]. The resistant cells were main-
tained for further three months in the presence or absence of
AZD1152. Genome-wide screening studies revealed that the
expression of the ABCB1 (ATP-binding cassette, subfamily B,
member 1/Multidrug resistance protein 1) gene was 70-fold
higher in the SW620 AZD1152-resistant clones than in the
SW620 cell line. At the same time, LC-MS (Liquid
chromatography-mass spectrometry) analysis showed de-
creased drug accumulation in cytoplasm of resistant cells.
When drug resistant SW620 cell line was treated with either
50 or 100 mg/kg of AZD1152, no decrease in tumor size was
observed. By contrast, the MiaPaca pancreatic carcinoma cell
line became resistant to AZD1152 following overexpression of
the ABCG2 (ATP-binding cassette, subfamily G, member
2/Breast cancer resistance protein) drug transporter. Microarray
analysis revealed that the expression of this gene was increased
98-fold relative to controls. [91].
Seamon et al. obtained JNJ-7706621 resistant HeLa cell
line by exposing the cells to increasing concentrations over
a 12 month period [92]. A LC-MS study on these resistant
lines showed a highly significant reduction of intracellular
drug accumulation. Quantitative RT-PCR (Real time poly-
merase chain reaction) studies revealed a 163-fold increase
in ABCG2 (BCRP/Breast cancer resistance protein) trans-
porter gene expression, a 37-fold increase in ABCC2 (ATP-
binding cassette, subfamily C, member 2), and a 3-fold
increase in ABCB1. Treatment of the resistant HeLa cell
line with the ABCG2 inhibitor fumitremorgin C restored the
sensitivity to JNJ-7706621 and mitoxantrone [92].
Unlike previous studies, in which resistant cell cultures
were developed by prolonged exposure to slowly-increasing
levels of AKIs, Girdler et al. [93] treated the HCT116 cell
line with a supralethal dose of ZM447439 (1 μM) for four
weeks. While most of the cells died, 20 drug resistant
colonies were appeared and among them seven clones were
selected for further characterization. Colony formation and
cell proliferation assays demonstrated that the clones R1 and
R2 were highly resistant to ZM447439 compared to con-
trols. cDNA sequencing of Aurora B from these resistant
clones (designated R1-R7), revealed five point mutations.
R3, R4, and R6 harbored two point mutations. H250Y was
common to all three of these clones, whereas G160V was
specific to R3 and R4, while G160E was specific to R6. The
R1, R2, R5, and R7 clones contained the G160E, Y156H
and L308P, H250Y, and Y156H mutations, respectively.
Ectopic expression of the Y156H, G160V, and H250Y
mutants in DLD-1 cells revealed that they retained catalytic
activity. The Y156H genotype along with G160V and
G160E showed strong cross-resistance to VX-680 and hes-
peradin, but not H250Y. Advanced crystallographic studies
revealed that these Aurora B mutations increase the steric
hindrance in the active site of Aurora B, inhibiting the
binding of ZM447439, but not that of ATP [93].
Validity of Aurora kinases as oncology targets
Although AKs are widely considered as oncogenes, many
questions were raised regarding their role in cancer initiation.
Despite their overexpression in many tumors, no clear role for
the AKs in tumorigenesis has been established. Probably the
overexpression of AKs may not be the main cause of cancer
initiation in primary tumors, rather it could be a late event.
Bischoff et al. showed that overexpression of wild type Aurora
A is sufficient to transform rat1 and NIH3T3 fibroblasts.
Authors also speculated that additional oncogenic events may
be required for transformation [94]. However, another similar
study performed by Tatsuka et al., did not observe transform-
ing potential of Aurora A alone in BALB/c 3T3A31-1 cells.
Interestingly in co-transfection study, Aurora A forced expres-
sion potentiated G12VH-Ras induced transformation [95]. Ota
et al. reported that overexpression of Aurora B induced histone
H3 phosphorylation (Ser10) and mitotic phenotype in Chinese
hamster embryo cells [96]. Further, when these cells were
xenografted into mice, they were able to form aggressive and
invasive tumors compared to control cells that express low
Aurora B. Nonetheless, another similar study performed by
Kanda et al. did not observed transforming potential of Aurora
B alone in BALB/c 3T3 A31-1-1 cells. Here also forced
expression of Aurora B augmented the frequency of G12V
H-Ras induced transformation [97]. Role of Aurora C in
transformation has not been yet established. All these studies
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clearly suggest that AKsmay not be directly involved in cancer
initiation, but rather cooperate with or complement other onco-
genes. Overexpression of AKs and their association with poor
prognosis were reported consistently in many cancers, indicat-
ing that AKs are required for tumor maintenance, progression,
and survival. These important functions of AKs are sufficient
to consider them as viable targets in cancer disease, even
though their clinical validation is still awaited.
Among the AKs, which Aurora kinase is the best target for
effective cancer treatment has become an interesting topic of
debate. Some reports suggest Aurora A inhibition has more
cytotoxic than cytostatic effects [98], while others suggest
targeting Aurora B is more effective [99]. MLN8237 is a highly
specific and potent Aurora A inhibitor, which has been shown
to induce apoptosis rapidly compared to other AKIs. It has also
been shown to have anticancer activity on a wide range of
cancer cell lines, such as MM cell lines. In clinical studies, it
produced few side effects and had good pharmacokinetics and
efficacy. Interestingly, MLN8237 has also displayed higher
anticancer activity than standard agents in childhood cancer
cell lines and their xenograft models. However, its efficacy
under the pediatric clinical setting needs further studies.
AZD1152 is a specific and potent Aurora B inhibitor, which
is currently at the forefront of clinical studies compared to other
Aurora inhibitors. It has been found to induce anticancer activ-
ity in both leukemias and solid tumors. It also induces rapid
apoptosis in many cancer cell lines, suggesting it has cytotoxic
activity. After AZD1152 administration, 15 patients with pro-
gressive cancer showed stable disease.
Dose limiting target toxicities of AKIs
Under in vitro conditions AKIs displayed broad anticancer
activity in rapidly proliferating cancer cells, but not in resting
cells. Hence it is likely that chemotherapy with AKIs may be
toxic to rapidly dividing hematological cells. As anticipated,
the most common on-target toxicity reported for manyAKIs is
grade 3/4 neutropenia. The other on-target toxicities reported
include wide range of hematological toxicities including leu-
kopenia and myelosuppression. Few cases of septicemia and
pneumonia were also reported and they may be the conse-
quences of neutropenia. On the other hand off-target toxicities
were also reported for AKIs, which includes hypertension,
somnolence, mucositis, stomatitis, proctalgia, grade 3 increase
in aspartate aminotransferase, and grade 2 ventricular dys-
function. Importantly most of the side effects were reversible
upon drug withdrawal. VX-680 caused cardio-toxicity and
was associated with death of one patient, which prompted to
suspend the compound from clinical trials recently. Probably
the off-target toxicities of AKIs could be due to their cross-
reaction with other kinases, since their spectrum varies from
among individual AKIs.
AKIs described in this review displayed much high po-
tency in hematological cancers both under in vitro and in
vivo conditions compared to solid tumors. This clearly
suggests that AKIs are highly active in rapidly cycling cells.
This point corresponds to the dose limiting toxicity includ-
ing bone marrow suppression and associated neutropenia in
normal hematological cells. Drug related toxicities of AKIs
on hematological cells and associated bone marrow toxicity
was reported exceptionally well by Wilkinson et al. [71].
Bone marrow tissue from the AZD1152 treated rats were
used to study the effect on rapidly dividing cells. Staining of
the tissue revealed signs of atrophy associated with decrease
in the total cellular content. However, myelosupression was
reversed within a week of AZD1152 withdrawal. Clinicians
should consider intermittent dosings at appropriate intervals
or metronomic therapy in order to better target tumor cells
and allowing bone marrow cells to recover.
Administration of hematopoietic growth factors in con-
junction with anticancer drugs may also help to reduce the
severity of bone marrow toxicities. Many clinical studies were
performed using growth factors in conjunction with anticancer
agents and were successful to limit the bone marrow related
toxicities [100]. In the context of AKIs, Cohen et al. used
G-CSF in conjunction with PHA-739358 [34]. In this
study they were able to escalate the PHA-739358 dose
until 1000 mg/m2 and did not reported any bone mar-
row related toxicities, particularly neutropenia. This was
the first time they were able to achieve objective
responses in patients with advanced solid tumors. On
the other hand, grade 3/4 neutropenia and neutropenic
infection were reported in the absence of G-CSF at
around 500 mg/m2 dose. Conjunctive use of growth
factors would be beneficial in significantly reducing
drug associated toxicities and also to enhance the effi-
cacy of drugs by dose intensification.
Additional features of AKIs
From our review, one can appreciate many important
aspects of AKIs. Firstly, almost all the AKIs cross-reacts
with many structurally related oncogenic kinases including
VEGFR2, FLT3, Bcr-Abl, JAK, and FGFR1. It has been
consistently reported that these kinases are involved in the
initiation and its progression of cancer. The main advantage
of targeting multiple kinases other than AKs is that majority
of cancers have abnormalities at multiple targets, thereby
increasing the probability of effective treatment. Targeting
multiple kinases may also prevent the emergence of resis-
tance during AKI therapy, because resistance towards AKIs
in the clinic is highly probable. To support this, recently
Girdler et al. reported emergence of resistance in HCT116
cell line due to Aurora B mutations [93].
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Secondly, we noticed that some pan-AKIs are significantly
effective in drug resistant cancer lines. They were able to
inhibit the cell proliferation equally or more efficiently com-
pared to non-resistant parent cell lines. The authors of these
studies were also able to successfully validate the AKIs ability
to overcome the (multidrug) resistance in xenograft models at
least with few AKIs. Hence AKIs may have a huge potential
to overcome the resistance in patients with refractory cancers
and some clinical studies are underway. Imatinib targeted
towards Bcr-Abl has been highly successful in treating CML
patients with Bcr-Abl translocation. In some patients complete
hematological and cytological responses were achieved. How-
ever, during the course of imatinib chemotherapy, many
patients acquired Abl kinase domain mutations resulting in
imatinib resistance. Among multiple mutations, the gate keep-
er mutation, namely T315I is very aggressive, which renders
complete resistance to imatinib and related compounds. Many
AKIs were able to inhibit T315I Bcr-Abl mutations with high
specificity than wild type Bcr-Abl. AKIs have also been
proved to be efficient in reversal of resistance in T315I Bcr-
Abl CML cell lines both in vitro and in vivo. This sparked the
interest of testing the AKIs in refractory CML patients with
T315I mutations and many clinical studies are underway.
Discovery of AKIs efficiency in inhibiting T315I Bcr-Abl
formed a strong rationale in testing the existing second gen-
eration kinase inhibitors on drug resistant mutants.
Thirdly, AKIs have a great potential to enhance the
efficacy of other anticancer drug and radiation therapies,
which can be exemplified by some reports. MK-5108 sig-
nificantly enhanced the efficacy of docetaxel in HeLa-S3
and ES-2 cell lines both in vitro and in vivo [67]. Low
concentrations of VE-465 alone synergized with paclitaxel
and induced 4.5 fold greater apoptosis in 1A9 ovarian
cancer cell line [81]. On the other hand AZD1152 [101]
and PHA-680632 [79] greatly enhanced the effect of radia-
tion treatment. These findings have potential interest for
further clinical development. AKIs have broad anticancer
activity in most of the cancer cell lines tested. The above
described characteristics of AKIs make them very attractive
candidates for targeted therapy.
Potential approvable AKIs for routine clinical use
In preliminary clinical studies, AKIs have consistently dis-
played cytostatic effects, tumor response or stable disease,
particularly in solid tumors. However, because of the plethora
of synthetic AKIs with diverse chemical structures, target and
off-target activities, toxicological profiles, and efficacy, it is
difficult to predict which compound(s) will enter clinical use.
Certainly, one of the most interesting and advanced inhibitors
is PHA-739358. This compound not only inhibits AKs, but it
also has an off-target effect onAbl, Ret, and FGFR-1 oncogenic
kinases, which are implicated in many types of malignancies.
Moreover, it has been shown to have good pharmacokinetic
properties combined with high anticancer activity; 28/80
patients with solid tumors showed stable disease, which lasted
for 6 months in six patients. As a result of these attributes PHA-
739358 is regarded as a highly promising clinical candidate.
Metastasis of a malignant tumor is one of the hallmarks of
cancer and its progression. Hence, inhibition of metastasis by
suppressing angiogenesis is a novel approach for cancer treat-
ment. Interestingly, CYC116 and ENMD-2076 inhibits
VEGFR-2, which directly promotes angiogenesis. These drugs
have also exhibited significant anticancer effects on a broad
range of cancer cell lines. These properties strongly encourage
their further clinical development, which could improve overall
survival of patients. AT9283 is a promising multikinase inhib-
itor with activity against, e.g., AKs, JAK2, JAK3, and Abl. In
one clinical trial, 30% of patients showed stable disease, and the
compound was well tolerated. One of the common mechanism
of cancer cell drug resistance is the overexpression of PgP,
which actively effluxes the anticancer agent before reaching
the target. Overexpression of PgP and associated multidrug
resistance was reported in cancer patients that are resistant to
many anticancer agents. AMG-900 was able to overcome the
resistance particularly in PgP upregulated multidrug resistant
cancer cell lines. AMG-900 may have great potential in both
enhancing the therapeutic potential of anticancer agents and
also in combating drug specific resistance.
Clinical efficacy of Aurora kinase inhibitors
Though AKIs have showed broad range anticancer activity in
cell lines and xenograft models, they did not lived up to the
expectations in the clinic. Here we speculate some of the
reasons; firstly the rationale for targeting AKs is not validated.
The main reason for targeting AKs is based on the fact that
they are upregulated inmany cancer types. It could be possible
that tumors cells may not be addicted to AKs for their prolif-
eration and survival as much as to Bcr-Abl, K-ras, or B-Raf
oncogenes. Recently many questions were raised regarding
the validity of AKs as oncogenes. Probably the role of AKs in
inducing malignant phenotype is transient. This is probably
one of the reasons that AKIs were not specifically efficient in
any cancer type, compared to other routinely used anticancer
agents in the clinic. For example platinum drugs are well
known agents to treat ovarian and breast cancers, paclitaxel
for ovarian and breast cancers, gemcitabine for pancreatic and
lung cancers, and bortezomib and thalidomide for multiple
myeloma. Secondly, polo-like kinases (PLK) share similar
functions that are assigned to AKs [101]. This is strongly
supported by the fact that cellular phenotypes overlap with
the inhibition of PLKs and AKs. Thus it is likely that PLKs
may complement the functions of AKs and may compromise
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the AKIs induced effects. Hence outcome of combined inhi-
bition of AKs and PLKs might be desirable compared to
single target inhibition. Thirdly, mitotic inhibitors are well
validated to treat cancer cells in vitro and in xenograft models,
where tumors doubling times are relatively short. However, in
real life situation human tumor cells have very long doubling
times that may range frommonths to years. AKIs execute their
mode of actions only when the cells are actively proliferating,
as AKs are predominantly expressed in mitotic phase. In
clinical trials, AKIs mostly induced only stable diseases (only
in few patients), but rarely the partial or complete responses
and this could be due to high doubling time of tumors cells.
Most of the AKIs doses employed in the Phase I studies are
relatively low, ranging from 3 to 200 mg/kg, due to DLTs,
mainly neutropenia. These doses are well below the thera-
puetic window for activity. Thus further dose enhacements in
Phase II studies in conjunction with growth factors would be
beneficial. Cohen et al. succesfully escalated the doses upto
1000 mg/m2 in the presence of G-CSF and reported objective
responses with reduced toxicities [34]. One of the solutions
could be intermittent dosings at appropraite intervals or met-
ronomic therapy to recover bone marrow cells should be
considered.
Conclusions
The AKs have been the focus of considerable attention since
their discovery inDrosophilamutants, and many independent
studies have contributed to our understanding of their biology.
AKs have multiple important functions in mitosis, and their
overexpression in some cancers prompted the discovery and
development of novel AKIs as therapeutic drugs using a
variety of experimental and computational techniques. Less
than ten years after AKs were discovered in humans, more
than ten Aurora inhibitors had entered clinical trial, and the
number of new AKIs entering preclinical development or
clinical trials is continuing to increase. No general mecha-
nisms of tumor cell resistance to AKIs have yet been identi-
fied, although some preliminary studies suggest that
mutations of the targeted Aurora kinase and overexpression
of drug-resistance genes may be involved.
Further in-depth clinical studies are now required to evaluate
the effectiveness of AKIs. Hence, it is too early to draw any
conclusions regarding which compounds are likely to enter the
market for routine use. Furthermore, identification of bio-
markers based on gene expression studies, that are predictive
of anticancer activity for a specific drug in individual patients is
important. Some AKIs have been shown to be very effective in
single agent or combination studies in some patients. Widely
accepted functional pharmacological/surrogate biomarkers are
available for both Aurora A and B inhibition, which makes
them attractive targets. In the absence of tumor associated
biomarkers, neutropenia per se is a biomarker of Aurora kinase
inhibition in the bone marrow cells. Thus, biomarkers that
allow the efficacy of givenAKI to be assessed offer the promise
of individualized therapy, which academic clinicians are keen
to pursue. Since AKIs are emerging as targeted cancer thera-
peutics with interesting off-target effects, one might reasonably
hope that they could also be used to tackle the problem of
resistance, and thus enhance the treatment of cancer.
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